Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study of Isatuximab, Pomalidomide and Dexamethasone combination for multiple myeloma patients who previously received Lenalidomide and Proteasome Inhibitor therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Greece
  • Study on the Safety and Effectiveness of Motixafortide and G-CSF for Stem Cell Collection in Patients with Multiple Myeloma

    Not recruiting

    3 1
    Investigated Drugs:
    Germany Hungary Italy Spain
  • Study of Teclistamab with Daratumumab or Lenalidomide for Elderly Patients with Newly Diagnosed Multiple Myeloma

    Not recruiting

    2 1 1 1
    France
  • Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Austria Belgium Czechia Denmark Finland France +10
  • Study on Isatuximab and Dexamethasone for Patients with Relapsed Multiple Myeloma Undergoing Stem Cell Transplantation

    Not recruiting

    2 1 1 1
    Italy
  • Study on Adding Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Germany
  • Study on Early Treatment with Teclistamab and Talquetamab for Patients with Newly Diagnosed High-Risk Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Spain
  • Study Comparing Bortezomib, Melphalan, Prednisone, Lenalidomide, and Daratumumab for Multiple Myeloma in Patients Ineligible for Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Italy
  • Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Italy
  • Study of Talquetamab and Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    Spain